Everest Organics Past Earnings Performance
Past criteria checks 1/6
Everest Organics's earnings have been declining at an average annual rate of -37%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 4.2% per year. Everest Organics's return on equity is 0.4%, and it has net margins of 0.1%.
Key information
-37.0%
Earnings growth rate
-38.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 4.2% |
| Return on equity | 0.4% |
| Net Margin | 0.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Everest Organics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,962 | 2 | 181 | 0 |
| 30 Sep 23 | 1,870 | 19 | 183 | 0 |
| 30 Jun 23 | 1,845 | 26 | 166 | 0 |
| 31 Mar 23 | 1,839 | -2 | 175 | 0 |
| 31 Dec 22 | 1,884 | 0 | 183 | 0 |
| 30 Sep 22 | 1,915 | -15 | 176 | 0 |
| 30 Jun 22 | 1,942 | -37 | 168 | 0 |
| 31 Mar 22 | 2,016 | 11 | 173 | 0 |
| 31 Dec 21 | 1,914 | 31 | 172 | 0 |
| 30 Sep 21 | 1,933 | 70 | 168 | 0 |
| 30 Jun 21 | 1,907 | 123 | 157 | 0 |
| 31 Mar 21 | 1,821 | 137 | 157 | 0 |
| 31 Dec 20 | 1,835 | 155 | 155 | 0 |
| 30 Sep 20 | 1,747 | 132 | 151 | 0 |
| 30 Jun 20 | 1,706 | 112 | 136 | 0 |
| 31 Mar 20 | 1,679 | 109 | 144 | 0 |
| 31 Dec 19 | 1,741 | 79 | 144 | 0 |
| 30 Sep 19 | 1,740 | 96 | 138 | 0 |
| 30 Jun 19 | 1,706 | 99 | 121 | 0 |
| 31 Mar 19 | 1,563 | 75 | 129 | 0 |
| 31 Dec 18 | 1,363 | 61 | 117 | 0 |
| 30 Sep 18 | 1,232 | 36 | 113 | 0 |
| 30 Jun 18 | 1,157 | 20 | 98 | 0 |
| 31 Mar 18 | 1,125 | 17 | 107 | 0 |
| 31 Dec 17 | 1,056 | 23 | 100 | 0 |
| 30 Sep 17 | 1,063 | 23 | 100 | 0 |
| 30 Jun 17 | 1,067 | 17 | 88 | 0 |
| 31 Mar 17 | 1,074 | 14 | 94 | 0 |
| 31 Dec 16 | 1,105 | 26 | 91 | 0 |
| 30 Sep 16 | 1,057 | 14 | 86 | 0 |
| 30 Jun 16 | 985 | 7 | 76 | 0 |
| 31 Mar 16 | 997 | 2 | 78 | 0 |
| 31 Dec 15 | 1,018 | -2 | 78 | 0 |
| 31 Mar 15 | 1,062 | 17 | 75 | 0 |
| 31 Dec 14 | 1,042 | 7 | 67 | 0 |
| 31 Mar 14 | 965 | 9 | 61 | 0 |
| 31 Dec 13 | 879 | 5 | 53 | 0 |
| 30 Sep 13 | 852 | 7 | 52 | 0 |
| 30 Jun 13 | 818 | 7 | 50 | 0 |
Quality Earnings: 524790 has a large one-off gain of ₹50.5M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 524790 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524790's earnings have declined by 37% per year over the past 5 years.
Accelerating Growth: 524790 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 524790 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.1%).
Return on Equity
High ROE: 524790's Return on Equity (0.4%) is considered low.